
NEW BLOOD
Hematology world
sit back, relax, and read on.

"Do not go where the path may lead. Instead, go where there is no path and leave a trail"
[Voxelotor] novel hemoglobin S polymerization inhibitor for the treatment of sickle cell anem
Mechanism of action Sickle cell disease is characterized by deoxygenated sickle hemoglobin (HbS) polymerization. The genetic mutation...
Vitamin B12 deficiency mimicking acute leukemia
Vitamin B12 deficiency can cause extensive hematologic alterations such as pancytopenia, macrocytosis, hypersegmentation of neutrophils,...
MASAC management of acute bleeding while on Emicizumab and recommendations on surgical management
Recommendations on Acute Bleed Management – PwHA without inhibitors No serious adverse events have been observed related to concomitant...
ISTH 2021: New guidelines on DOAC use in obese patients
Previously, the 2016 guidance from the ISTH suggested not using DOACs in people with BMI >40 kg/m2 and weight >120 kg. The new...
Luspatercept in thalassemia decrease transfusion burden
Luspatercept For beta thalassemia [decrease blood transfusion burden ] an erythroid maturation agent, is approved for anemia in adults...
[DOAC] in APS
The Use of Direct Oral Anticoagulants [DOAC] in Antiphospholipid Syndrome H&O What is antiphospholipid syndrome, and what causes it?. HC ...
Rituximab or splenectomy: which second-line therapy for wAIHA
Rituximab is becoming the preferred second-line therapy for wAIHA, with an 80% overall response rate, a median response time of 3 to 6...
Acute Antiplatelet Therapy Acute Stroke Management
• All acute stroke patients not already on an antiplatelet agent and not receiving alteplase therapy should be given at least 160 mg of...
[VITT]Vaccine-Induced Immune Thrombotic Thrombocytopenia
Backg round: Vaccines are a critical tool in the management of the COVID-19 pandemic resulting from SARS-CoV-2. Recently, AstraZeneca...
Blood donation is a Healthy Habit
The benefits of blood donation are as follows: It orients the donor towards positive thinking. Boosts the production of red blood cells-...
VTE RECURRENCE
Risk of VTE Recurrence The risk of recurrent VTE after stopping anticoagulants appears to be similar whether anticoagulant therapy is...
Safety and efficacy of DOACs in obese patients
No randomized controlled trials have examined the safety and efficacy of DOAC in obese patients . Background: According to the Health...
Guideline recommendations for treatment of cancer-associated VTE
National Comprehensive Cancer Network 2020 for patients without GI malignancies Apixaban (category 1), edoxaban after at least 5 days of...
Treatment of massive and submassive Pulmonary Embolism
Approximately 3% to 5% of patients with an acute PE present with hemodynamic compromise, defined as a systolic blood pressure ,90 mm Hg...
Management of adults with ITP who are corticosteroid dependent or has no response to steriod
In adults with ITP for 3 months or not responded to steriod SECOND-LINE THERAPIES: SPLENECTOMY, TPO-RA, AND RITUXIMAB Recommendation In...
Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce painful VOC IN SCA
Hydroxyurea, indicated for managing sickle cell anemia (SCA), and L-glutamine, indicated for treating sickle cell disease (SCD), were the...
TREATMENT OF TTP IN PREGNANCY
Daily therapeutic PEX has to be started as soon as possible (at least 1 but preferably 1.5 plasma volume exchanges daily), with plasma...



















